Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
Cadrenal Therapeutics, Inc. (CVKD) had Return on Tangible Equity of -143.17% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
-- |
|
$-10.65M |
|
-- |
|
-- |
|
$10.96M |
|
$-10.96M |
|
$0.31M |
|
$-10.65M |
|
$-10.65M |
|
$-10.65M |
|
$-10.65M |
|
$-10.65M |
|
$-10.65M |
|
$-10.96M |
|
$-10.96M |
|
1.22M |
|
1.22M |
|
$-8.73 |
|
$-8.73 |
|
| Balance Sheet Financials | |
$10.11M |
|
$0.01M |
|
$0.01M |
|
$10.12M |
|
$2.68M |
|
-- |
|
-- |
|
$2.68M |
|
$7.44M |
|
$7.44M |
|
$7.44M |
|
1.78M |
|
| Cash Flow Statement Financials | |
$-7.36M |
|
$-0.01M |
|
$8.98M |
|
$8.40M |
|
$10.02M |
|
$1.62M |
|
$1.42M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
3.77 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-7.36M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-143.17% |
|
|
Return on Tangible Equity |
-143.17% |
-105.21% |
|
-143.17% |
|
$4.17 |
|
$-6.04 |
|
$-6.03 |
|